MedKoo Cat#: 558290 | Name: Valilactone
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Valilactone is a fatty acid synthase inhibitor produced by a cultured strain of soil actinomycetes. Fatty acid synthase (FAS) is necessary for growth and survival of tumor cells and is a promising drug target for oncology.

Chemical Structure

Valilactone
Valilactone
CAS#113276-96-3

Theoretical Analysis

MedKoo Cat#: 558290

Name: Valilactone

CAS#: 113276-96-3

Chemical Formula: C22H39NO5

Exact Mass: 397.2828

Molecular Weight: 397.56

Elemental Analysis: C, 66.47; H, 9.89; N, 3.52; O, 20.12

Price and Availability

Size Price Availability Quantity
5mg USD 600.00
10mg USD 1,000.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Valilactone; (-)-Valilactone
IUPAC/Chemical Name
1-((2S,3R)-3-hexyl-4-oxooxetan-2-yl)heptan-2-yl formyl-L-valinate
InChi Key
WWGVIIVMPMBQFV-HNNZKPGWSA-N
InChi Code
InChI=1S/C22H39NO5/c1-5-7-9-11-13-18-19(28-21(18)25)14-17(12-10-8-6-2)27-22(26)20(16(3)4)23-15-24/h15-20H,5-14H2,1-4H3,(H,23,24)/t17?,18-,19+,20+/m1/s1
SMILES Code
CC(C)[C@@H](C(OC(C[C@@H]([C@H]1CCCCCC)OC1=O)CCCCC)=O)NC=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 397.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Richardson RD, Ma G, Oyola Y, Zancanella M, Knowles LM, Cieplak P, Romo D, Smith JW. Synthesis of novel beta-lactone inhibitors of fatty acid synthase. J Med Chem. 2008 Sep 11;51(17):5285-96. doi: 10.1021/jm800321h. Epub 2008 Aug 19. PMID: 18710210; PMCID: PMC3172131. 2: Ma G, Zancanella M, Oyola Y, Richardson RD, Smith JW, Romo D. Total synthesis and comparative analysis of orlistat, valilactone, and a transposed orlistat derivative: Inhibitors of fatty acid synthase. Org Lett. 2006 Sep 28;8(20):4497-500. doi: 10.1021/ol061651o. PMID: 16986934. 3: Wu Y, Sun YP. An expeditious enantioselective total synthesis of valilactone. J Org Chem. 2006 Jul 21;71(15):5748-51. doi: 10.1021/jo060844m. PMID: 16839158. 4: Yoshinari K, Aoki M, Ohtsuka T, Nakayama N, Itezono Y, Mutoh M, Watanabe J, Yokose K. Panclicins, novel pancreatic lipase inhibitors. II. Structural elucidation. J Antibiot (Tokyo). 1994 Dec;47(12):1376-84. doi: 10.7164/antibiotics.47.1376. PMID: 7844032. 5: Kitahara M, Asano M, Naganawa H, Maeda K, Hamada M, Aoyagi T, Umezawa H, Iitaka Y, Nakamura H. Valilactone, an inhibitor of esterase, produced by actinomycetes. J Antibiot (Tokyo). 1987 Nov;40(11):1647-50. doi: 10.7164/antibiotics.40.1647. PMID: 3693135.